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Ruth Andrew1,2 and Natalie Z. M. Homer2Abstract
Steroid hormone profiling has historically underpinned ad-
vances in endocrine investigation and research, crucially
dependent on selective and sensitive hormone assays. Mining
the “steroidome” by mass spectrometry (MS) provides greater
specificity than immunoassays. Building on a 50 year legacy,
gas and liquid chromatography-MS continue to evolve (e.g.
sequential derivatisation, mobile phase modifiers). Exciting
new technology (e.g. imaging, ion mobility, supercritical fluid),
sample preparation (microextraction, molecular imprinted
polymers) are advancing the field. Automated analysis of wider
profiles of steroids is within reach, in smaller and more varied
sample types, including molecular mapping of tissue sections.
These new analytical dimensions require rigorous validation
and advanced statistics. This review highlights that MS con-
tinues to open new windows of biochemical understanding in
endocrinology.
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During the last century, endocrinologists have become
increasingly reliant on sensitive and specific measure-
ments of hormones to understand the pivotal roles of
steroids in health and disease, dissecting intricate
regulation of homeostatic processes (reproduction,
stress responses, metabolism to name a few). Immuno-
assays opened the first doors to steroid detection in the
1960s, underpinning many key discoveries and are still
widely used today, appreciated for their rapidity and
ease of automation and use. However when levels of
steroids are low, specificity of immunoassays has been
called into question [1]. Cross-reactivity with similar
compounds and over-estimation can be particularly
problematic with sex steroids, notably estrogens and 5a-
dihydrotestosterone, creating conflicting data in sub-
jects of certain age groups, between genders and
following treatments. No matter how careful one is,
there may be unknowns in the biological matrix that
cross react with the antibody leading to inaccurate
measurements. Moreover, immunoassays for steroids are
usually restricted to measuring single analytes rather
than multi-steroid profiles, although multiplexing has
been achieved in other settings, e.g. cytokine bead
arrays. Although immunoassays continue to evolve (e.g.
immunocomplexes [2], surface enhanced Raman scat-
tering [3] and lateral flow [4] assays), these concerns
prompted the Endocrine Society to publish a position
statement in 2013 [5], and to assemble the “Sex Steroid
Assays Reporting Task Force” recommending that clin-
ical steroid biochemistry should be supported by mass
spectrometry (MS) and guiding current publishing
standards [6].
MS is an analytical technique that measures charged
molecules or ions in the gaseous state. Samples are
ionised, separated in a mass analyser according to their
mass-to-charge ratio (m/z) and ions quantified by rela-
tive abundances. Coupled to separation techniques such
as gas (GC) or liquid chromatography (LC), MS is
regarded as the gold standard for steroid hormone
analysis, based on its precision and accuracy, but the
aspiration of global application to comprehensively
profile steroids across wide dynamic ranges (Figure 1)
has been hard to achieve [7]. Successful implementa-
tion of MS to steroid bioanalysis has required techno-
logical advances of all stages of analytical workflows,
including sample preparation, separation, ionisation andrrent Opinion in Endocrine and Metabolic Research 2020, 15:71–78
Figure 1
Steroids circulate in concentrations, which span across 5 orders of
magnitude and in an even wider ranges in disease or in children. The
graph shows concentrations in plasma/serum in adults, in some cases
separated by males and females and stages of the menstrual cycle and
pregnancy. F = cortisol; B = corticosterone; Aldo = aldosterone;
P4 = progesterone; E1 = estrone; E2 = estradiol; T = testosterone;
A4 = androstenedione; DHT = dihydrotestosterone; 1 = pre-menopausal;
2 = post-menopausal; L = Luteal phase; T1 = trimester 1; T2 = Trimester 2;
T3 = Trimester 3; Tx = treatment. Triangular columns depict steroids
where lower amounts are less clear use to limits of assay sensitivity.
72 Breast Cancermass analysis (Figure 2). MS has become more acces-
sible and automated meaning it can be employed in
wider settings, but specialist scientists are still essential
to drive innovation. Technology advances have allowed
application to smaller - “microsampling” - and more
varied sample types [8,9]. We can now study spatial
intracrinology rather than only levels in fluids, through
MS imaging. Here we highlight the advances over the
last few years which continue to unravel endocrine,
paracrine and intracrine complexity and place MS at the
forefront in delivering systems endocrinology in the
post-genomic era.Ionisation for detection
At the heart of any MS analysis is the intrinsic need to
ionise molecules of interest, which for steroids presents
the first challenge. Steroids must either gain (often for
glucocorticoids, progestogens and androgens) or lose
charges (often for estrogens and aldosterone) but these
lipophilic molecules have a low propensity to ionise.
This problem is exacerbated in the presence of
competing biomatrix molecules, so-called “matrix ef-
fects” which can present as ion suppression or ion
attenuation. Overcoming these phenomena e essen-
tially battling invisible, unknown confounders e is key
to minimising analytical variability and has required
decades of innovation (Figure 2) with still more
required, especially when trying to down-size, analyseCurrent Opinion in Endocrine and Metabolic Research 2020, 15:71–78tissue and extend clinical quality standards into the
preclinical arena.The art of separation
Separation of steroids in advance of MS analysis is
common, hailing from pioneering work by Shackleton
et al. in the 1970s [10], profiling steroids using GC to
characterise in-born errors of metabolism, and this
approach has been adopted world-wide. This initial
profile of 17 steroids has led the way for detailed
screening in clinical biochemistry and research labs,
with iterations benefitting from instrument advances
e.g. single quadrupole mass analysers transitioning to
tandem MS for enhanced specificity [11,12]. Ion trap
technology has been implemented but thus far proved
less popular [13]. The high resolving power of GC
column technology has enabled increasing numbers of
analytes (e.g. 52 by Wang et al. [14]) to be recovered
from a wider range of matrices. Recently a drive to un-
derstand the holistic steroidome [15] has sparked in-
terest in approaches that exploit sequential
derivatisation [12] of different chemical groups charac-
terising several steroid classes within one assay, and thus
enabling chemical sub-types of steroids to be screened
concomitantly. Innovative use of sub-fractionation
combining electron impact and atmospheric pressure
chemical ionisation in conjunction with GC have added
breadth [16]. Derivatisation has also been used effec-
tively to encourage extraction from tissues, demon-
strated with breast adipose [17]. These approaches offer
new opportunities in pathway mapping, while being
highly beneficial in reducing sample volume [12]. GC
has only recently been interfaced with high resolution
MS which will bring new opportunities and GC/GC is an
exciting field to watch [18].
While GC yields excellent separation and remains a
mainstay, applications using LC-MS/MS emerged once
electrospray ionisation was more widely adopted, paving
the way to the practical realisation of the position
statement [5] in clinical biochemistry; LC often offers
higher throughput by faster preparation workflows and
reduced analysis time. Testosterone and cortisol, being
abundant, were relatively swiftly switched to MS anal-
ysis in clinical biochemistry and research settings, but
estrogens, particularly in lower ranges (Figure 1),
presented challenges, for example assessing effective-
ness of aromatase inhibitors in women recovering from
breast cancer, where residual hormone may promote
tumour regrowth [19]. Although the resolving power of
LC is not as good as GC, ongoing improvements in LC
technology are enabling multi-steroid profiling, albeit
some steroids having poorer sensitivity and isomer sep-
aration remains challenging [20,21]. A further benefit of
LC over GC is the ability to include conjugates in the
analyte profile [22]. Moreover steroids are now an in-
tegral part of metabolomics screens [23] e.g. cancerwww.sciencedirect.com
Figure 2
50 Decades of Advances in Steroid Mass Spectrometry. 2D = 2 dimensional; APCI–atmospheric pressure chemical ionisation; APPI = atmospheric
photoionisation; CI = chemical ionisation; EI = electro impact; ESI = electrospray; GC = gas chromatography; HPLC = high performance liquid chro-
matography; LC = liquid chromatography; LLE = liquid– liquid extraction; MS = mass spectrometry; MS/MS = tandem MS; Prep = sample preparation;
qToF = quadrupole-time of flight; SFC = supercritical fluid; SLE = supported liquid extraction; SPE = solid phase extraction; UHPLC = ultra-HPLC;
UPSFC = ultra performance SFC.
Mass spectrometry and steroids Andrew and Homer 73biomarkers. Over time column performance has
improved, with alternative chemistries (e.g. biphenyl
[24]) and smaller particle sizes offering greater surface
area for interactions. As the field progressed from high
performance liquid chromatography (HPLC) to ultra-
HPLC (UHPLC), MS sensitivity has benefitted from
associated reduced flow of mobile phase. Further mini-
aturisation through micro-LC [25], is now possible with
associated economic, environmental and sustainability
benefits. Like with GC, 2 dimensional automated sep-
aration is starting to gain traction [26].
Although sensitivity improves with instrument ad-
vances, derivatisation combined with LC to improve
ionisation remains beneficial for ultimate sensitivity
[22,27,28]. Derivatives append to specific chemicals
groups, such as ketones or hydroxyls, and there is now
increased interest in combining measurements of deri-
vatised and underivatised steroids (e.g. estrogens and
glucocorticoids respectively [29]), or derivatised ste-
roids with conjugates [22], or parallel [30] derivatisation
of two distinct chemical groups e all these approaches
widen analytical profiles. Judicious use of mobile phase
additives is gaining popularity to enhance sensitivity
including stable lithium adducts [31] avoiding dehy-
dration, and ammonium fluoride [32] which allows
positive-negative switching and hence combinedwww.sciencedirect.com Cuanalysis of “negative”- estrogens and aldosterone - and
“positive “steroids - glucocorticoid progestogens and
androgens. Summed Multiple Reaction Monitoring
[7,32] is more commonplace, whereby multiple specific
transitions are consolidated to increase sensitivity.What lies beneath
MSworkflows look for “known knowns” and, despite the
excellent qualities of LC and GC, analytical specialists
are always acutely aware of what might be hidden from
view. Numerous steroidal isomers and closely related
molecules within the biomatrix can co-elute and share
m/z values and thus the field must continue to explore
orthogonal separation to peel away the layers of chemical
complexity. Capillary electrophoresis drew early interest
as an alternative separation approach [33,34] but this
has not yet reached common use. In contrast however,
ultra-performance supercritical fluid chromatography
(UP-SFC) has found a renaissance with revised instru-
ment design enabling safety and throughput [35].
Whether this approach will find a leading edge remains
untested, but is a chromatographic space to watch
[36,37], with great potential to improve isomer resolu-
tion through orthogonal molecular interactions and also
enhanced sensitivity through more facile desolvation. By
way of example, De Kock et al. separated 19 steroids
within 5 min using this approach [36].rrent Opinion in Endocrine and Metabolic Research 2020, 15:71–78
74 Breast CancerThe shape of things to come
Ion mobility separation (IMS) is the exciting new kid on
the block, separating ions through collision cross section
(CCS) and bringing a yet further dimension to separa-
tion. Ion mobility was developed to separate larger
molecules and, although differences in CCS of steroids
are much smaller, they appear tractable to the technique
[38], particularly with the resolving power of IMS
already improving e.g. with cyclic IMS. Ion mobility can
be used in conjunction with chromatography to filter out
unknown isobaric interferents and increasing confidence
in data. In the absence of chromatography, ion mobility
allows shotgun approaches and improves specificity in
imaging workflows. Again derivatisation has a place, to
enhance CCS differences (e.g. estrogen isomers [39]),
while increasing ion intensity in the fight against matrix
effects.Fishing in the biological pool
Sole reliance on chromatographic separation for sample
clean-up can be a mistake that will come back to bite the
analyst and indeed simple methods reliant on protein
precipitation can suffer badly from matrix effects.
Extraction of steroids from biological matrices is highly
beneficial prior to introduction into the instrument. In
recent years sample preparation has moved away from
manual liquideliquid extraction, firstly to supported
liquid extraction (SLE) [40], and increasingly towards
automated and miniaturised solid phase extraction [32].
A bewildering array of high-quality support matrices are
available, with reverse and ion-exchange chromatog-
raphy being most popular, and new technologies
constantly evolving e.g. cyclodextrin based polymers
[41]. These technologies have advanced with increas-
ingly robustness, less reliance on wetting and offering
facile removal of phospholipids, the most common
source of matrix effects. In the last few years we see the
field teetering on bespoke “analyte matched SPE” using
Molecular Imprinted Polymers (MIPs [42e45] which
act as “chemical antibodies” through mirroring the SPE
matrix to the shape of the analyte, with multiplexing
possible. This approach may allow stereospecific
extraction, an important conceptual interface with
biology through the many examples of steroid isomer
pairs in vivo with differing bioactivity (e.g. 17a and b
isomers of testosterone and estradiol and the many hy-
droxy metabolites of estrogens [28]). Many novel ap-
proaches to extraction are coming to the fore through
the environmental field, including microwave extraction
[46,47], metal organic frameworks [48], magnetic ionic
liquid extraction [49,50], and pressurized liquid
extraction [51].Scanning the depths
Additional analytical specificity can be achieved through
high-resolution MS, where mass is determined withCurrent Opinion in Endocrine and Metabolic Research 2020, 15:71–78greater accuracy. Empirical formulae may be assigned
and more granular measurement of m/z achieved to
distinguish ions. High resolution instrumentation has
become more accessible during the last 10 years, but
there remains much debate as to its benefits as an
alternative to tandem MS for quantitation. Despite the
apparent advantages in selectivity, doubts remain
regarding the dynamic range and the robustness of
quantitation. Opportunities in this space are still to be
fully exploited, with only a few applications as yet
coming through [18,26,52,53].The spatial frontier
Sampling without chromatography through tissue im-
aging of steroids was first achieved by Cobice et al. [54]
for glucocorticoids. The approach of MS imaging is an
exciting application of matrix assisted laser desorption
ionisation (MALDI) and desorption electrospray ioni-
sation (DESI) technology, allowing a sampling device to
raster across tissue surface harvesting the ions of interest
and then reconstruction of regional maps (Figure 3).
Steroids, with their low ionizability, require derivatisa-
tion in this setting, matched to steroid class. Basic MS
imaging does not permit separation but innovations such
as ion mobility and chromatography coupled to liquid
extraction surface analysis (LESA) technology [55] offer
routes to overcoming isobaric interferences that other-
wise would limit data value e.g. DHEA interfering with
testosterone due to being the same mass. This may also
be overcome by fragmentation/MS3 in conjunction with
imaging [56,57]. The approach is semi-quantitative and
requires careful multi-dimensional data analysis and
normalisation, and standardisation is challenging. Mass
cytometry is also reaching clinical application [58] but
will require step-changes in sensitivity to allow visual-
isation of steroids at a cellular level. New matrices are
coming to the fore better suited to ionize steroids, such
as poly(3,4-ethylenedioxythiophene)/graphene [59].Data complexity, validation and community
standards
Lastly it is important to acknowledge that with
increasing data complexity comes the need for different
approaches to data handling and a greater focus on
community standards. A number of (inter)national QC
schemes operate now allowing both clinical and research
labs to align, benefitting from bespoke reference ranges
[60] where stable-isotope dilution is the gold-standard
for quantitation with the added advantage of chro-
matographic peak tracking. Samples are enriched with
an isotopologue of the analyte to correct for variation
introduced through matrix effects, sample processing
and instrumentation. Stable-isotope labelled internal
standards are increasingly available commercially for
clinically relevant steroids but for bespoke research
assays may need to be synthesized in-house, a highly
challenging and skilled task, which requires high puritywww.sciencedirect.com
Figure 3
MS Imaging to Visualise Intracrinology. Mass Spectrometry imaging offers the ability to localise steroid distribution across tissue sections. Ionisation
can be achieved through means such as matrix assisted laser desorption ionisation (MALDI) and desorption electrospray ionisation (DESI) from tissue or
cells and images reconstructed into heatmaps which can be aligned with histology.
Mass spectrometry and steroids Andrew and Homer 75as an end point. 13C and deuterium are the most popular
isotopes, where the internal standard selected must
carry sufficient labels to avoid interference with natu-
rally occurring isotopologues, for steroids, enrichment
with a minimum of 3 heavy isotopes. Analysts must
ensure the lack of contribution of measurable unlabelled
analyte in the internal standard, or make quantitative
adjustment during validation if present. Although less
common these days, in the absence of stable-isotope
labelled standards, analysts may correct to positional
isomers or molecules from the same chemical class but
the inferiority of this approach is evident in poorer
precision and accuracy [28]. The position of the
enriched isotopes also matters so that ideally the pre-
cursor and product ions both carry the labels. 13C stan-
dards are preferred for derivatisation approaches where
deutero-hydrogen exchange may occur in the presence
of chemical catalysts and labels lost during sample
processing and even in-source. This has been a focus of
new derivatisation approaches in recent years [28,61].
Validation criteria for analytical methods have become
better described by the Food and Drugs (FDA) [62],
European Medical Agencies (EMA) [63] and the bio-
analytical community in the last decade for non-
endogenous compounds, where stringent requirements
are in place for assay linearity, precision and accuracy
(e.g. 15% relative standard deviation (RSD) in replicates
except at the lower limit of quantitation, where 20%
RSD is acceptable). However these benchmarks still
remain controversial for endogenous biomarkers, mainly
due to the lack of analyte-free matrix. Selecting an
appropriate surrogate matrix is an important step in
validation and in the case of steroids, charcoal-stripped
plasma or serum can be used but detectable levels,www.sciencedirect.com Cusometimes remain, even with double stripping, and
must be assessed before validation. Draft guidelines
from The International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human
Use [64] suggest that 25% RSD for endogenous bio-
markers in method validation is acceptable, as long as
this can be scientifically justified [65]. The FDA
recognise that some characteristics of validation may not
apply but have not as yet changed their guidelines to
address this.
The use of certified standard solutions and certified
reference materials is expected in regulatory studies and
is fast becoming a prerequisite for publication to raise
quality and agreement in the field; some Quality Con-
trol schemes make patient samples available to allow
comparison between clinical labs, but still only for a
limited number of most clinically relevant steroids. In
general quantitation of steroids should continue aim to
match to FDA and EMA [62,63] guidance and there are
some excellent tutorial articles available to guide
[66,67].
Plug-in methods by manufacturers are making the
field more robust and increasing its accessibility, and
best practice for sampling handling and storage is
being addressed formally [68]. However to fully mine
the rich multi-profile datasets, engagement with new
methods of data handling are needed, for example
isotope deconvolution analysis to improve calibration
[69]. Harvesting the concept of the “steroid metab-
olomic profile” [70] requires multi-variate statistical
analysis and machine learning has recently been
explored to exciting effect in diagnostics of adrenal
cancer [15].rrent Opinion in Endocrine and Metabolic Research 2020, 15:71–78
76 Breast CancerConclusions
Steroidomics, harvesting 2D or 3D multi-hormone pro-
files generated by mass spectrometry, has blossomed
over the last few years, building on a rich history of
innovation. Over the last few years researchers have
taken a more holistic look at endocrine health and dis-
ease, in conjunction with other strands of the ‘omics
field. This field of analytical chemistry continues to
benefit from technology advances in chromatography
and mass spectrometry, and is poised to harvest current
opportunities presented at the interface of chemistry
and systems biology.Conflict of interest statement
Nothing declared.Priority papers
No 5: Position statement from the Endocrine Society
marking the need for mass spectrometry to improve the
quality of steroid analysis. This statement drove the
need for researchers to work with analytical chemists to
apply MS techniques to their best advantage. Over
recent years this has meant that researchers have
continued to explore the most recent instrument and
chemical advances in the field to push down limits of
detection, minimise sample volume, improve quality of
analysis and explore alternative matrices.
No 15: This paper demonstrates how machine learning
can be applied to GCMS data to devise fingerprints of
health and disease. The researcher successfully identi-
fied profiles of biomarkers of adrenal carcinoma.
No 18: Gas Chromatography coupled with MS has been
the mainstay of steroid analysis and the technology
remained relatively static until recently where we now
see it being interfaced with high-resolution MS and also
converted to 2 dimensional chromatography. This paper
shows an approach that combines GC/GC with high
resolution MS and demonstrates the benefits that can
be gained from the extra levels of specificity. It opens
doors to untargeted screening and demonstrates the
value of accurate MS in identifying unknowns.
No 37: Supercritical Fluid chromatography (SFC) has
been recognised as a potential separating technique for
several decades but has recently become more acces-
sible through instrument advances. This recent paper
makes detailed comparisons between SFC and gas
chromatography, showing the strength of the technique
in multi-hormone profiling.
No 38: Hernandez- Mesa et al. developed a database of
collision cross sections of steroidal molecules demon-
strating this parameter is a useful orthogonal approach toCurrent Opinion in Endocrine and Metabolic Research 2020, 15:71–78achieve separation and developing a publicly available
database to enable the field. Ion mobility is poised to be
used both in conjunction with chromatographic and
imaging workflows to enhance specificity and enable
shotgun approaches.
No 54: Cobice et al. were the first group to achieve
tissue mapping of steroids using MS imaging. They
applied derivatisation approaches to the tissue surface
to enhance the signal of keto-steroids and developed a
novel approach to map steroids by MALDI sampling.
This approach has been developed further to other keto-
steroids and oxysterols.
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